905703-97-1

Ganitumab (AMG 479; 1 mg/dose; i.p; Na?ve and tumor-bearing mice) inhibits IGF1-induced activation of mIGF1R in murine lungs^[1].
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils^[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3^[1].